Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
Global CNS Therapeutics market is projected to reach US$ 106190 million in 2029, increasing from US$ 76300 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CNS Therapeutics market research.
Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CNS Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Segment by Type
Segment by Application
By Region
The CNS Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CNS Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Neurodegenerative Diseases
1.2.3 Mood Disorders
1.2.4 Schizophrenia
1.2.5 Autism
1.2.6 Depression
1.3 Market by Application
1.3.1 Global CNS Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CNS Therapeutics Market Perspective (2018-2029)
2.2 CNS Therapeutics Growth Trends by Region
2.2.1 Global CNS Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CNS Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 CNS Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 CNS Therapeutics Market Dynamics
2.3.1 CNS Therapeutics Industry Trends
2.3.2 CNS Therapeutics Market Drivers
2.3.3 CNS Therapeutics Market Challenges
2.3.4 CNS Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CNS Therapeutics Players by Revenue
3.1.1 Global Top CNS Therapeutics Players by Revenue (2018-2023)
3.1.2 Global CNS Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global CNS Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CNS Therapeutics Revenue
3.4 Global CNS Therapeutics Market Concentration Ratio
3.4.1 Global CNS Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CNS Therapeutics Revenue in 2022
3.5 CNS Therapeutics Key Players Head office and Area Served
3.6 Key Players CNS Therapeutics Product Solution and Service
3.7 Date of Enter into CNS Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CNS Therapeutics Breakdown Data by Type
4.1 Global CNS Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global CNS Therapeutics Forecasted Market Size by Type (2024-2029)
5 CNS Therapeutics Breakdown Data by Application
5.1 Global CNS Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global CNS Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CNS Therapeutics Market Size (2018-2029)
6.2 North America CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CNS Therapeutics Market Size by Country (2018-2023)
6.4 North America CNS Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CNS Therapeutics Market Size (2018-2029)
7.2 Europe CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CNS Therapeutics Market Size by Country (2018-2023)
7.4 Europe CNS Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CNS Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific CNS Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CNS Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific CNS Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CNS Therapeutics Market Size (2018-2029)
9.2 Latin America CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CNS Therapeutics Market Size by Country (2018-2023)
9.4 Latin America CNS Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CNS Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CNS Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa CNS Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer CNS Therapeutics Introduction
11.1.4 Pfizer Revenue in CNS Therapeutics Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Company Detail
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals CNS Therapeutics Introduction
11.2.4 Janssen Pharmaceuticals Revenue in CNS Therapeutics Business (2018-2023)
11.2.5 Janssen Pharmaceuticals Recent Development
11.3 Allergan
11.3.1 Allergan Company Detail
11.3.2 Allergan Business Overview
11.3.3 Allergan CNS Therapeutics Introduction
11.3.4 Allergan Revenue in CNS Therapeutics Business (2018-2023)
11.3.5 Allergan Recent Development
11.4 Lundbeck
11.4.1 Lundbeck Company Detail
11.4.2 Lundbeck Business Overview
11.4.3 Lundbeck CNS Therapeutics Introduction
11.4.4 Lundbeck Revenue in CNS Therapeutics Business (2018-2023)
11.4.5 Lundbeck Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva CNS Therapeutics Introduction
11.5.4 Teva Revenue in CNS Therapeutics Business (2018-2023)
11.5.5 Teva Recent Development
11.6 Camber Pharmaceuticals
11.6.1 Camber Pharmaceuticals Company Detail
11.6.2 Camber Pharmaceuticals Business Overview
11.6.3 Camber Pharmaceuticals CNS Therapeutics Introduction
11.6.4 Camber Pharmaceuticals Revenue in CNS Therapeutics Business (2018-2023)
11.6.5 Camber Pharmaceuticals Recent Development
11.7 Zhejiang Haisen Pharmaceutical
11.7.1 Zhejiang Haisen Pharmaceutical Company Detail
11.7.2 Zhejiang Haisen Pharmaceutical Business Overview
11.7.3 Zhejiang Haisen Pharmaceutical CNS Therapeutics Introduction
11.7.4 Zhejiang Haisen Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
11.7.5 Zhejiang Haisen Pharmaceutical Recent Development
11.8 Jewim Pharmaceutical
11.8.1 Jewim Pharmaceutical Company Detail
11.8.2 Jewim Pharmaceutical Business Overview
11.8.3 Jewim Pharmaceutical CNS Therapeutics Introduction
11.8.4 Jewim Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
11.8.5 Jewim Pharmaceutical Recent Development
11.9 Cipla
11.9.1 Cipla Company Detail
11.9.2 Cipla Business Overview
11.9.3 Cipla CNS Therapeutics Introduction
11.9.4 Cipla Revenue in CNS Therapeutics Business (2018-2023)
11.9.5 Cipla Recent Development
11.10 Merck Sharp & Dohme Corp.
11.10.1 Merck Sharp & Dohme Corp. Company Detail
11.10.2 Merck Sharp & Dohme Corp. Business Overview
11.10.3 Merck Sharp & Dohme Corp. CNS Therapeutics Introduction
11.10.4 Merck Sharp & Dohme Corp. Revenue in CNS Therapeutics Business (2018-2023)
11.10.5 Merck Sharp & Dohme Corp. Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly CNS Therapeutics Introduction
11.11.4 Eli Lilly Revenue in CNS Therapeutics Business (2018-2023)
11.11.5 Eli Lilly Recent Development
11.12 GlaxoSmithKline
11.12.1 GlaxoSmithKline Company Detail
11.12.2 GlaxoSmithKline Business Overview
11.12.3 GlaxoSmithKline CNS Therapeutics Introduction
11.12.4 GlaxoSmithKline Revenue in CNS Therapeutics Business (2018-2023)
11.12.5 GlaxoSmithKline Recent Development
11.13 Novartis
11.13.1 Novartis Company Detail
11.13.2 Novartis Business Overview
11.13.3 Novartis CNS Therapeutics Introduction
11.13.4 Novartis Revenue in CNS Therapeutics Business (2018-2023)
11.13.5 Novartis Recent Development
11.14 LUPIN
11.14.1 LUPIN Company Detail
11.14.2 LUPIN Business Overview
11.14.3 LUPIN CNS Therapeutics Introduction
11.14.4 LUPIN Revenue in CNS Therapeutics Business (2018-2023)
11.14.5 LUPIN Recent Development
11.15 ZYDUS PHARMS
11.15.1 ZYDUS PHARMS Company Detail
11.15.2 ZYDUS PHARMS Business Overview
11.15.3 ZYDUS PHARMS CNS Therapeutics Introduction
11.15.4 ZYDUS PHARMS Revenue in CNS Therapeutics Business (2018-2023)
11.15.5 ZYDUS PHARMS Recent Development
11.16 Biogen
11.16.1 Biogen Company Detail
11.16.2 Biogen Business Overview
11.16.3 Biogen CNS Therapeutics Introduction
11.16.4 Biogen Revenue in CNS Therapeutics Business (2018-2023)
11.16.5 Biogen Recent Development
11.17 Otsuka Pharmaceutical
11.17.1 Otsuka Pharmaceutical Company Detail
11.17.2 Otsuka Pharmaceutical Business Overview
11.17.3 Otsuka Pharmaceutical CNS Therapeutics Introduction
11.17.4 Otsuka Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
11.17.5 Otsuka Pharmaceutical Recent Development
11.18 Astra Zeneca
11.18.1 Astra Zeneca Company Detail
11.18.2 Astra Zeneca Business Overview
11.18.3 Astra Zeneca CNS Therapeutics Introduction
11.18.4 Astra Zeneca Revenue in CNS Therapeutics Business (2018-2023)
11.18.5 Astra Zeneca Recent Development
11.19 Takeda
11.19.1 Takeda Company Detail
11.19.2 Takeda Business Overview
11.19.3 Takeda CNS Therapeutics Introduction
11.19.4 Takeda Revenue in CNS Therapeutics Business (2018-2023)
11.19.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research